Well this is instant impact!

Just a few weeks after UP released our blockbuster study on the enormous economics and health benefits of speeding up new drug approval process, the Trump administration has announced new rules to bring new life-saving drugs to market faster.

According to the new policy announced on Monday:

“The FDA pilot program would shorten the time it takes from drug identification to first-in-human Phase 1 clinical trials; additionally, FDA is clarifying regulatory expectations for sponsors that could reduce early trial timelines by six to 12 months. FDA has also issued draft guidance clarifying that, in many cases, one high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient to provide substantial evidence of effectiveness in support of a drug approval.”

If fully implemented, this is a momentous step in saving lives and reducing pain and suffering for potentially millions of Americans suffering from cancer, MS, Parkinson’s, diabetes, epilepsy, Alzheimer’s, and other cruel disabling diseases.

Congratulations to President Trump, HHS Secretary Robert F. Kennedy Jr., and FDA Commissioner Marty Makary for this long-overdue reform.

Congratulations also to UP senior fellow Tomas Phillipson (who served as a chief economist for Trump in his first term) for his research that helped launch this new policy.

The Unleash Prosperity Now study (as highlighted in the WSJ last month), reported that speeding up drug approval could save hundreds of millions of years of life of Americans and would unlock between $10 trillion and $49 trillion in economic value.

Just three weeks after the study was posted and brought to the attention of President Trump, the FDA new policy was announced.